escitalopram / Generic mfg. - LARVOL DELTA

Clinical outcomes in patients with multiple myeloma and antidepressant use: A retrospective cohort study (ASH 2025) - "Adult patients with multiple myeloma since 2010 and prescribed antidepressants (sertraline, escitalopram, citalopram, paroxetine, fluoxetine, fluvoxamine, venlafaxine, duloxetine, trazodone, mirtazapine, or bupropion) were identified using ICD-10 diagnostic and RxNorm codes. While some associations were modest in magnitude, the consistent pattern of increased risk suggests that pre-existing depression and its treatment may identify a more vulnerable subgroup of multiple myeloma patients. Further prospective studies are needed to clarify underlying mechanisms and to evaluate the potential impact of early psychiatric intervention."

Clinical data • Retrospective data • Chronic Kidney Disease • CNS Disorders • Depression • Hematological Malignancies • Infectious Disease • Major Depressive Disorder • Multiple Myeloma • Musculoskeletal Diseases • Nephrology • Renal Disease

Treatment of apathy in stroke patients: a systematic review. (PubMed, Front Neurol) - "Pharmacological interventions with escitalopram and donepezil (alone or combined with intensive language action therapy) showed potential benefits. Nefiracetam yielded mixed results depending on dose and coexisting depression...Nevertheless, evidence remains scarce and heterogeneous, underscoring the need for larger, high-quality randomized controlled trials to establish definitive treatment guidelines. https://www.crd.york.ac.uk/PROSPERO/view/CRD42022332559."

Clinical • Journal • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Depression • Hematological Disorders • Psychiatry

Escitalopram and the Risk of Serious Adverse Events (clinicaltrials.gov) - P=N/A | N=13675 | Completed | Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Adverse events • New trial • Serious adverse event • Chronic Kidney Disease • Nephrology • Renal Disease

Acute Blockade of the Serotonin Transporter With Low Doses of Escitalopram Does Not Alter the Behavioural Responses to Acute Psilocybin. (PubMed, Eur J Neurosci) - "We found that acute psilocybin administration increased locomotor activity and induced head twitches, and that escitalopram did not alter these effects. Our study using low doses of escitalopram reveals no direct involvement of 5-HTT in mediating the acute effects of psilocybin in mice, and instead suggests that developmental changes and varying serotonin levels may rather explain the absence of psilocybin's acute behavioural effects previously reported in the 5-HTT homozygous knockout mice."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

The Comparative Efficacy of Antidepressant and Psychological Therapies on Cognition in Depression: A Systematic Review and Network Meta-Analysis. (PubMed, Neuropsychol Rev) - "Common antidepressants, including escitalopram, citalopram, paroxetine and fluoxetine were not significantly different from placebo in improving cognition. The findings suggest that, among antidepressants, vortioxetine is the sole treatment improving cognition in depression. The effects were however small, highlighting the need for the development of MDD interventions targeting cognition."

Journal • Retrospective data • Review • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

OXTR rs2254298 polymorphism influences escitalopram response in Generalized Anxiety Disorder: a sex-specific role for oxytocin signaling. (PubMed, Front Psychiatry) - "Our findings suggest that the OXTR rs2254298 polymorphism may influence escitalopram response in GAD via OT neuroendocrine mechanisms, exhibiting prominent sexual dimorphism. Integrating genetic profiling with endocrine biomarkers holds promise for personalizing anxiety treatment."

Journal • CNS Disorders • General Anxiety Disorder • Mood Disorders • Psychiatry

Psychiatric Medications Procurement at Primary Health Centers (PHCs) in Tumkur: Insights from an Effectiveness Implementation Hybrid Randomized Controlled Trial on Mental Health Tele-mentoring of Primary Care Doctors (PCDs). (PubMed, Indian J Psychol Med) - "Within-group analysis over time showed a statistically significant increase in the proportion of PHCs procuring amitriptyline in both the OMHT arm (p = .01) and the TAU arm (p = .03). Additionally, in the OMHT arm, there was a significant increase over time in the proportion of PHCs procuring alprazolam (p = .03) and clonazepam (p = .02). In the between-group comparison of total quantities procured during the combined training and post-training phases, the OMHT arm demonstrated significantly higher procurement of escitalopram (p < .01) and risperidone (p < .01) compared to the TAU arm, indicating greater confidence in prescribing practices of key psychiatric medications among trained PCDs. Clinical Trials Registry of India (CTRI/2024/02/062906)."

Journal • CNS Disorders • Mental Retardation • Psychiatry

Adjustment for dispensed doses does not explain higher antidepressant concentrations in post-mortem toxicology. (PubMed, Br J Clin Pharmacol) - "Dose adjustment generally did not improve the separation of poisoning vs non-poisoning suicides, indicating that post-mortem concentrations may not have clear dose-concentration relationships."

Journal

Hyperfiltration and Metabolism Before and After a Low-Calorie, Pre-Gastric Bypass Surgery Diet: Significance for Concentrations of Hydrophilic and Lipophilic Drugs. (PubMed, Basic Clin Pharmacol Toxicol) - "The greater the individual weight loss, the greater the concentration increase in hydrophilic drugs that undergo glomerular filtration, for example, pregabalin and gabapentin, suggesting that this reflects decreased glomerular hyperfiltration. By contrast, for highly lipophilic drugs, for example, mirtazapine and sertraline, the greater the individual creatinine and cystatin C loss, the greater the decrease in drug concentration, interpreted as increased drug metabolism based on decreased liver inflammation and steatosis. Venlafaxine/O-desmethylvenlafaxine displayed a complicated pattern suggesting the involvement of both glomerular filtration and metabolism. Serum concentrations of modestly lipophilic drugs, for example, duloxetine and (es)citalopram, were not significantly affected by the diet. In conclusion, hydrophilicity- and lipophilicity-related changes in drug concentrations over the diet period covary with markers of changes in hyperfiltration and metabolism,..."

Journal • Genetic Disorders • Inflammation • CST3

Editorial: Enhancing therapeutic strategies: a focus on pharmacovigilance in new wave antidepressants and antipsychotics. (PubMed, Front Psychiatry) - No abstract available

Adverse events • Journal • CNS Disorders

MENO-ES: Analysis of Escitalopram Plasma Concentrations in Premenopausal and Postmenopausal Women (clinicaltrials.gov) - P=N/A | N=94 | Not yet recruiting | Sponsor: Eskisehir Osmangazi University

New trial • CNS Disorders • Depression • General Anxiety Disorder • Major Depressive Disorder • Mood Disorders • Psychiatry

MetaMDA: explainable prediction of microbe-drug association utilizing random walks on a microbe-metabolite-drug heterogeneous network. (PubMed, Bioinformatics) - "Notably, we show MetaMDA's unique ability to predict MDAs involving microbes or drugs absent from labeled data, as illustrated by associations related to acarbose. Furthermore, mechanistic analysis of MetaMDA provides biological explanations for the associations between E. coli and escitalopram, highlighting its potential to reveal a deeper mechanistic understanding of microbe-drug associations. The code and datasets are available on Zenodo https://doi.org/10.5281/zenodo.17348446 and GitHub https://github.com/wqlyt17/MetaMDA. Supplementary data are available at Bioinformatics online."

Heterogeneity • Journal • Oncology

Power Spectral Slope as a Novel Brain Functional Marker for Major Depressive Disorder. (PubMed, Biol Psychiatry Glob Open Sci) - "A subset of 52 patients with MDD also underwent rs-fMRI scanning after a 12-week antidepressant treatment (escitalopram/duloxetine). The normalization effect of ventral striatum spectral slope following antidepressant treatment suggests a region-specific response. Taken together, the findings suggest that PSS may serve as a novel brain functional marker for MDD."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Opioid overdose associated with concomitant use of hydrocodone and selective serotonin reuptake inhibitors. (PubMed, BMC Med) - "In this cohort study, based on data from US healthcare claims databases, initiating citalopram, escitalopram, fluoxetine, or paroxetine while on hydrocodone was associated with an increased risk of opioid overdose compared with sertraline. No substantial risk differences were observed across SSRIs other than sertraline."

Journal • Retrospective data • Addiction (Opioid and Alcohol) • CNS Disorders • CYP3A4

Unraveling the cardiac consequences of hypothyroidism: a case report of sinus arrest and bradycardia exacerbated by seasonal changes, escitalopram and medication noncompliance. (PubMed, Oxf Med Case Reports) - "Herein, we report a case of a 53-year-old woman with hypothyroidism who experienced episodes of prolonged sinus arrest, which resolved following temporary pacing and initiation of levothyroxine therapy. Factors such as seasonal variation, medication noncompliance, recent viral illness, and concurrent escitalopram use likely contributed to her presentation. This case highlights the importance of prompt recognition and management of hypothyroid-related cardiac arrhythmias."

Journal • Cardiovascular • Endocrine Disorders • Infectious Disease

Serotonin Signaling Pathway Modulation Affects Retinal Neuron Survival in Experimental Model of Retinal Ischemia. (PubMed, Life (Basel)) - "Following MFA, PhNR remained stable in SSRI-treated animals, whereas a significant impairment was observed in the vehicle-treated group. These findings demonstrate that Escitalopram provides neuroprotection by reducing both functional and structural damage in the retina and may represent a promising therapeutic strategy for retinal neurodegeneration."

Journal • Cardiovascular • CNS Disorders • BDNF

Contrasting Effects of Larval Escitalopram and Serotonin-Synthesis Inhibitor on Adult Phototaxis in Drosophila w1118. (PubMed, Life (Basel)) - "These findings support the hypothesis that serotonin modulates behavioral predictability and mean choice bias; variability effects were compound-specific (escitalopram modestly increased MADn, whereas 5-HTP did not differ from Control). Given the rising costs and ethical constraints of vertebrate models, our results highlight Drosophila and FlyVac as a powerful, cost-effective system for investigating SSRI effects on decision phenotypes."

Journal

Targeted Biocatalyst Design for Asymmetric Citalopram Conversion in a Membrane Reactor. (PubMed, Pharmaceutics) - "In the resolution of citalopram, the system achieved 96% conversion of S-citalopram within 24 h, with the enantiomeric excess of 93% in favor of the S-ester over the R-ester. These findings demonstrate the system's potential for efficient and stereoselective biocatalytic applications."

Journal

Efficacy and safety profile of vortioxetine as an add-on molecule in obsessive-compulsive disorder: a randomized double-blinded placebo-controlled superiority trial - a study protocol. (PubMed, BMC Psychiatry) - "Vortioxetine's unique pharmacological profile may offer significant benefits to managing cognitive symptoms and improving the quality of life of OCD patients. This clinical trial aims to provide evidence on the clinical value and safety of vortioxetine in the management of OCD in order to advance the optimization of more effective and personalized treatment plans."

Clinical • Clinical protocol • Head-to-Head • Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

Seizure Risk in an Adolescent Using Semaglutide: A Case Report (AES 2025) - "She was intubated and treated with 3000 mg levetiracetam (Keppra). This case suggests that GLP-1 agonists like semaglutide, which may induce hypoglycemia, particularly when combined with additional factors such as a family history of epilepsy and the use of medications like escitalopram, may contribute to the risk of seizures. Healthcare providers should consider recent weight loss and GLP-1 agonist use as possible contributing factors when evaluating new-onset seizures. Further research is needed to better understand the potential effects of GLP-1 agonists in precipitating seizures."

Case report • Clinical • CNS Disorders • Epilepsy • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Mood Disorders • Obesity • Psychiatry • Type 2 Diabetes Mellitus

Agitation in Alzheimer's disease: From assessment to therapeutics. (PubMed, World J Psychiatry) - "For chronic agitation, serotonin-selective reuptake inhibitors, especially citalopram and escitalopram, are often preferred due to safety concerns associated with the long-term use of antipsychotics. Promising novel strategies, such as new compounds and neuromodulation, are likely to be incorporated into agitation therapeutics in the next few years."

Journal • Review • Alzheimer's Disease • CNS Disorders • Dementia • Depression • Mood Disorders • Psychiatry

Escitalopram normalizes decreased left inferior frontal gyrus activation in social anxiety disorder during self-referential processing. (PubMed, Psychiatry Res Neuroimaging) - "SAD may be associated with decreased activation of the left inferior frontal gyrus to negative self-referential social cues. Escitalopram may normalize such activation. As left inferior frontal gyrus has been linked to inner speech while working on self-reflection tasks, the increased activation might relate to reappraising negative social cues."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Social Anxiety Disorder

Comparative BMI-z Changes With Initiation and Adherence to Antidepressant Medications Among Youth. (PubMed, J Am Acad Child Adolesc Psychiatry) - "Among youth, initiation and adherence to bupropion was not associated with 12-month BMI-z change, though four other most-common antidepressants were associated with small increases in BMI-z over this time. Clinicians should consider these differences when prescribing antidepressants to youth, alongside FDA approvals, clinical guidelines, and evidence of safety and efficacy."

Journal

Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial. (PubMed, Transl Psychiatry) - "Recent clinical trial data suggests that ratings on depression scales are lowered after psilocybin therapy compared to placebo, though it is unclear what neuropsychological mechanisms underpin these effects. Therefore, a more positive behavioural bias in emotional processing was seen following psilocybin and citalopram compared to baseline. This highlights the potential for at least some overlap in cognitive mechanisms across two distinct treatments, which is noteworthy given the short dosing regimen with psilocybin."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Treatment persistence and modification patterns of SSRIs in children and adolescents with depression: a nationwide population-based study in South Korea. (PubMed, BMC Psychiatry) - "Each SSRI exhibited distinct patterns of treatment modifications, with no single agent consistently outperforming the other agents. These findings highlight the need for individualized SSRI selection that considers both pharmacological profiles and patient characteristics in the real-world management of pediatric depression."

Journal • Retrospective data • CNS Disorders • Depression • Mood Disorders • Pediatrics • Psychiatry